Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INAB

+ Watchlist+ Portfolio

IN8bio, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.78
52-Week Range
$0.72 – $2.73
Market Cap
$8.35M
P/E (TTM)
—
EPS (TTM)
-1.00
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.54
PEG Ratio
—
Return on Equity
-141.83%
Return on Assets
-70.34%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
5.78
Debt/Equity
0.19
Total Debt
$2.75M
Free Cash Flow
$-7.93M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-2.79M

Market Snapshot

About

IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment. The company's innovative approach focuses on harnessing the unique properties of gamma-delta T cells, which can recognize and kill cancer cells without requiring HLA matching. IN8bio's lead programs target both hematological malignancies and solid tumors using allogeneic (off-the-shelf) gamma-delta T cell products. The company's technology platform aims to deliver more accessible and affordable cell therapies with reduced risk of graft-versus-host disease and improved manufacturing scalability.